MA
PBE icon

MUFG Americas’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

MUFG Americas’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-296
Closed -$12K – 1194
2014
Q1 		$12K Buy
+296
New +$12.7K ﹤0.01% 880

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
SAM
SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

MUFG Americas's PBE Position: Q2 2014 in Review

MUFG Americas sold out of Invesco Biotechnology & Genome ETF (PBE) in Q2 2014, closing a stake of 296 shares — an estimated $12K sold.

MUFG Americas first reported a position in PBE in Q1 2014 and held it in 1 quarter. The position peaked at $12K in Q1 2014. 74 funds tracked by Wall St. Rank hold PBE as of Q2 2014.

  • MUFG Americas reported no remaining Invesco Biotechnology & Genome ETF position as of Q2 2014 after selling out during the quarter.
  • MUFG Americas sold 296 Invesco Biotechnology & Genome ETF shares in Q2 2014, an estimated $12K.
  • MUFG Americas first reported a position in Invesco Biotechnology & Genome ETF in Q1 2014 and held it in 1 quarter.
  • MUFG Americas's Invesco Biotechnology & Genome ETF position peaked at $12K in Q1 2014.
  • 74 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2014.

Based on MUFG Americas's 13F filing for Q2 2014, filed 5 Aug 2014.